Zhang, T., Staats, J. S., Chan, C., Harrison, M. R., O’Donnell, P. H., Batich, K. A., … Weinhold, K. J. (2018). Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC). In Journal of Clinical Oncology (Vol. 36, pp. 4533–4533). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.4533

Zhang, Tian, Janet S. Staats, Cliburn Chan, Michael Roger Harrison, Peter H. O’Donnell, Kristen A. Batich, Tianling Chen, et al. “Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).” In Journal of Clinical Oncology, 36:4533–4533. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4533.

Zhang T, Staats JS, Chan C, Harrison MR, O’Donnell PH, Batich KA, et al. Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4533–4533.

Zhang, Tian, et al. “Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 4533–4533. Crossref, doi:10.1200/jco.2018.36.15_suppl.4533.

Zhang T, Staats JS, Chan C, Harrison MR, O’Donnell PH, Batich KA, Chen T, Krejsa C, Izumi R, George DJ, Weinhold KJ. Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 4533–4533.